Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility

P. Francioli, J. Etienne, R. Hoigne, J. P. Thys and A. Gerber
Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

OBJECTIVE--To evaluate the efficacy and safety of ceftriaxone sodium in the treatment of streptococcal endocarditis. DESIGN--An open, multicenter, noncomparative study with a follow-up of patients for 4 months to 5 years. SETTING--Internal medicine wards and outpatient clinics of hospitals of various sizes in three European countries. PATIENTS--Fifty-nine patients with defined criteria for streptococcal endocarditis. INTERVENTION--Ceftriaxone sodium administered at a once-daily dose of 2 g for 4 weeks. MAIN OUTCOME MEASURES--Clinical outcome and microbiological cure rate. RESULTS--Among the 59 patients, 55 completed the treatment and were followed up for 4 months to 5 years. No patients showed evidence of relapse. Treatment was completely uneventful in 42 patients (71%). A cardiac valve was replaced in four patients (7%) receiving antimicrobial therapy and in six patients (10%) who had completed antimicrobial therapy. One of the 10 valves taken for culture at surgery was positive, but only for microorganisms that were different from the microorganism isolated before the treatment. The treatment had to be interrupted in four patients because of drug allergy. Other side effects were mild except for two cases of reversible neutropenia. The treatment was easy to administer: 27 patients (46%) had no permanent intravenous catheter at any time, seven patients (12%) had such a catheter for less than 4 days. Twenty-three patients (39%) were discharged from the hospital less than 2 weeks after admission. CONCLUSIONS.--Ceftriaxone sodium administered at a once-daily dose of 2 g appears to be an effective and safe treatment of streptococcal endocarditis. In hospitals, this agent may be more convenient to administer than penicillin G with or without aminoglycosides. Some patients may even be treated as outpatients.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group
Wilson et al.
Journal of the American Dental Association 2008;139:3S-24S.
ABSTRACT | FULL TEXT  

Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group
Wilson et al.
Circulation 2007;116:1736-1754.
ABSTRACT | FULL TEXT  

Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group
Wilson et al.
Journal of the American Dental Association 2007;138:739-760.
ABSTRACT | FULL TEXT  

Antimicrobial treatment of infective endocarditis caused by viridans streptococci highly susceptible to penicillin: historic overview and future considerations
Verhagen et al.
J Antimicrob Chemother 2006;57:819-824.
ABSTRACT | FULL TEXT  

The role of aminoglycosides in combination with a {beta}-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials
Falagas et al.
J Antimicrob Chemother 2006;57:639-647.
ABSTRACT | FULL TEXT  

Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America
Baddour et al.
Circulation 2005;111:e394-e434.
ABSTRACT | FULL TEXT  

Guidelines for the antibiotic treatment of endocarditis in adults: report of the Working Party of the British Society for Antimicrobial Chemotherapy
Elliott et al.
J Antimicrob Chemother 2004;54:971-981.
ABSTRACT | FULL TEXT  

Unique Features of Infective Endocarditis in Childhood
Ferrieri et al.
Pediatrics 2002;109:931-943.
FULL TEXT  

Unique Features of Infective Endocarditis in Childhood
Ferrieri et al.
Circulation 2002;105:2115-2126.
FULL TEXT  

Antibiotic treatment of streptococcal, enterococcal, and staphylococcal endocarditis
Working Party of the British Society for Antimicro
Heart 1998;79:207-208.
FULL TEXT